PF-05206388 is under clinical development by Tenpoint Therapeutics and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PF-05206388’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PF-05206388 overview

PF-05206388 is under development for the treatment of acute wet age related macular degeneration. The drug candidate is a new molecular entity (NME). It is a human embryonic stem cell derived retinal pigment epithelium (RPE) living tissue equivalent. The drug candidate is administered through intraocular implant.

Tenpoint Therapeutics overview

Tenpoint Therapeutics conduct experimental development on natural sciences and engineering. Tenpoint Therapeutics is headquartered in Cambridge, England, the UK.

For a complete picture of PF-05206388’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.